makorin ring finger protein 9, pseudogeneGenealiases: MKRN5 · MKRN9 · MKRNP6 · RNF65 · ZNF127L3
Q-omics provides the consensus-scored MKRN9P profile across patient tissues and cancer cell-line models. MKRN9P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MKRN9P is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MKRN9P RNA expression shows 10,708 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where MKRN9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MKRN9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MKRN9P survival associations across molecular data types. MKRN9P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MKRN9P RNA expression–survival associations across cancer types. High MKRN9P expression shows unfavorable associations in KIRC, LUAD, KIRP and STAD, but favorable associations in MESO and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MKRN9P RNA expression.
This table summarizes MKRN9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MKRN9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MKRN9P shows lower tumor expression in KICH and higher tumor expression in THCA, COAD, HNSC, LUAD and PRAD. The THCA box plot shows higher MKRN9P RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with MKRN9P in patient tissues and cancer cell lines. In patient samples, MKRN9P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MKRN9P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
